Table 2.
Time to BM and incidences of BM within 2 years in total population and subgroups
| Subgroup | Time to BM (median, month)
|
P-value | Incidences of BM within 2 years (%)
|
P-value | ||
|---|---|---|---|---|---|---|
| Erlotinib group | Chemotherapy group | Erlotinib group | Chemotherapy group | |||
| Total patients (129 pairs) | 17.60 (15.55–19.65) | 15.37 (13.99–16.75) | 0.002 | 66.40 (55.23–77.57) | 84.50 (76.27–92.73) | 0.001 |
| First-line treatment (66 pairs) | 17.60 (15.59–19.61) | 15.20 (11.71–18.69) | 0.009 | 55.80 (38.94–72.66) | 86.50 (75.33–97.67) | <0.001 |
| Second-line treatment (63 pairs) | 18.13 (15.61–20.65) | 16.00 (14.44–17.56) | 0.048 | 61.20 (47.28–75.12) | 82.30 (70.15–94.45) | 0.016 |
| Stage IIIB (54 pairs) | 19.97 (6.54–33.40) | 18.63 (14.61–22.65) | 0.028 | 54.60 (36.37–72.83) | 77.20 (63.09–91.31) | 0.014 |
| Stage IV (75 pairs) | 16.50 (14.62–18.38) | 14.20 (11.45–16.95) | 0.009 | 75.50 (61.98–89.02) | 90.30 (80.70–99.90) | 0.027 |
| Exon 19 deletion (66 pairs) | 17.90 (15.08–20.72) | 16.23 (14.12–18.34) | 0.047 | 61.60 (46.12–77.08) | 80.90 (68.94–92.86) | 0.034 |
| Exon 21 L858R mutation (63 pairs) | 17.30 (14.70–19.90) | 14.60 (12.00–17.20) | 0.008 | 70.60 (55.12–86.08) | 89.10 (80.08–98.12) | 0.014 |
Note: Values within parentheses show 95% CI.
Abbreviations: BM, brain metastasis; CI, confidence interval.